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Abstract
Background: There have been various reports concerning Helicobacter cinaedi infections. However, few reports
have examined central nervous system infections.
Case presentation: A 52-year-old man was transferred from the local hospital because of a persistent headache
and suspected intracranial subdural empyema. Neurosurgical drainage was performed via burr holes. Gram staining
and results from abscess cultures were negative. The blood culture yielded H. cinaedi. He was given an antibiotic
regimen consisting of 2 g of ceftriaxone twice a day, but the size of the abscess was not reduced in size at all after
3 weeks of treatment. Neurosurgical drainage was performed again, and the antimicrobial regimen was switched to
2 g of meropenem 3 times a day. The size of the abscess was reduced after 2 weeks of the second drainage and
antimicrobial drug change to meropenem. After 4 weeks treatment with meropenem, the patient was discharged,
and his symptoms had completely resolved.
Conclusions: H. cinaedi infection should be considered in the differential diagnosis of subdural empyema cases for
which Gram staining and abscess culture results are negative. Meropenem can be a first-line drug of choice or an
effective alternative treatment for H. cinaedi central nervous system infections.
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Background
The first report of a Helicobacter cinaedi infection in-
volved a man with proctitis in 1984 [1]. Since then,
various foci of H. cinaedi infection have been re-
ported. However, few reports have examined central
nervous system (CNS) infections, and the optimal
therapy for CNS infection is unknown. Here, we re-
port a case of intracranial subdural empyema and
bacteremia due to H. cinaedi, in which the patient ex-
perienced treatment failure after a maximum dose of
ceftriaxone. Finally, he was treated successfully with
adequate drainage and meropenem.
Case presentation
A 52-year-old man with a history of epilepsy and
drug eruption due to an amoxicillin/clavulanate was
transferred from the local hospital because of a per-
sistent headache and a suspicion of chronic subdural
hematoma. There were no other symptoms before
the persistent headache occurred, and he could per-
form his work normally. He had no history of head
trauma and no meningeal irritation symptoms, such
as neck stiffness. He kept an outdoor dog for years,
but he had no contact with other animals, such as
rats, hamsters, dogs, cats, birds, or monkeys, during
the past year.
Computed tomography and nuclear magnetic reson-
ance imaging of the head showed a right subdural
mass with high and mixed density/intensity (Fig. 1a).
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Because of these findings, we suspected intracranial
subdural empyema (SDE).
Neurosurgical drainage was performed via burr
holes. Gram staining of the purulent material showed
no bacteria, and he had no predisposition for sinus-
itis or periodontal disease. Therefore, we thought the
possibility of anaerobic and aerobic gram-negative
bacteria involvement was low. Two sets of blood cul-
tures were drawn, and empirical antibiotic therapy
was started with intravenous vancomycin targeting
only aerobic streptococci and staphylococci. How-
ever, the results from abscess cultures were negative.
After 7 days of incubation, the blood culture (BAC-
TEC FX system, Nippon BD, Tokyo, Japan) yielded
Gram-negative, long spiral-shaped bacillus. Micro-
aerobic subculture on blood agar plates with hydro-
gen gas showed thin transparent colonies. Because of
these findings, we suspected Helicobacter cinaedi
intracranial subdural empyema. The human immuno-
deficiency virus antibody screening test administered
just after surgery showed negative results. An add-
itional two sets of blood culture specimens were
drawn, and he was given an antibiotic regimen con-
sisting of 2 g of ceftriaxone twice a day. The blood
culture results were negative, but the size of the ab-
scess was not reduced in size at all after 3 weeks of
treatment (Fig. 1b).
Neurosurgical drainage was performed again, and
the antimicrobial regimen was switched to 2 g of
meropenem 3 times a day. Although the microaero-
bic culture of the abscess was negative, H. cinaedi
was identified from the abscess and blood culture by
cdtB virulence factor gene-based PCR. The 16S rRNA
sequence analysis revealed with 100% similarity be-
tween the abscess and blood culture (Fig. 2).
Antimicrobial susceptibility testing for H. cinaedi
using the broth microdilution method revealed mini-
mum inhibitory concentrations (MICs) of 4 μg/mL
for ceftriaxone and 0.06 μg/mL for meropenem
(Table 1). The size of the abscess was reduced after
2 weeks of the second drainage and antimicrobial
drug change to meropenem (Fig. 1c). After 4 weeks
treatment with meropenem, the patient was dis-
charged, and his symptoms had completely resolved.
The patient has continued visiting the hospital for
more than 1 year after discharge, and there has been
no recurrence to date (Fig. 1d).
Conclusion
This case revealed two important clinical issues. First,
H. cinaedi can cause an intracranial SDE. Secondly,
treatment failure with ceftriaxone can occur when the
MIC value for ceftriaxone is 4 μg/mL or higher in an
H. cinaedi intracranial SDE case.
To our knowledge, this is the first published case of
H. cinaedi intracranial SDE. There have been four re-
ported cases of H. cinaedi central nervous system in-
fections. Three cases concerned meningitis in adults
[2–4], and the final case was a case of meningitis and
bacteremia in a neonate [5]. None of those reported
cases were associated with abscess formation. We
must consider H. cinaedi as a causative organism of
culture-negative intracranial SDE.
Treatment failure with ceftriaxone in cases of H.
cinaedi intracranial SDE can occur if the MIC value
for ceftriaxone is 4 μg/mL or higher. We initially
chose ceftriaxone as definitive therapy because anti-
biotic regimens including ceftriaxone effectively
treated H. cinaedi meningitis in the previous four
Fig. 1 Nuclear magnetic resonance imaging of the head and brain. a Gadolinium-enhanced T1-weighted imaging (Gd T1WI) at the time of ad-
mission showed right subdural empyema (white arrowhead, 106 × 33 × 53 mm) with mixed low intensity. b Gd T1WI after 3 weeks of treatment.
The size of the abscess was not reduced (white arrowhead, 109 × 35 × 60 mm). c Gadolinium-enhanced T1-weighted imaging 2 weeks after the
second drainage and antimicrobial drug change to meropenem. The abscess was decreased in size. d T1-weighted imaging without contrast,
1 year after the treatment. There was no recurrence of the abscess
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case reports. Antimicrobial susceptibility testing
(AST) for H. cinaedi isolates was not performed in
these cases, probably because AST for H. cinaedi is
too cumbersome to perform routinely in hospital la-
boratories [6].
However, in the present case, AST yielded useful
information for changing the therapeutic strategy.
With the doses normally used to treat bacterial men-
ingitis, the concentrations of ceftriaxone in cerebro-
spinal fluid range from 2 to 8 μg/mL, and levels are
nearly constant in children and adults [7, 8]. These
concentrations are close to the MIC observed in this
case (4 μg/mL), which may negate the culture results,
but there is a possibility of treatment failure especially
in the presence of an abscess. On the other hand,
when 2 g of meropenem was administered every 8 h,
the concentration in the cerebrospinal fluid was re-
ported to be 1.29 μg/mL, even in the trough value
[9], which is considerably higher than the MIC in this
case (0.06 μg/mL). Therefore, meropenem can be a
first-line drug of choice or an effective alternative
treatment for CNS infection, especially when the MIC
value is 0.06 μg/mL or lower.
In conclusion, H. cinaedi infection should be con-
sidered in the differential diagnosis of SDE cases for
which Gram staining and abscess culture results are
Fig. 2 Phylogenetic tree of helicobacter cinaedi. Neighbor-joining tree showing the position within the species of the genus Helicobacter, based
on 16S rRNA gene sequence. The numbers at the branching points are bootstrap values. Campylobacter fetus subsp. fetus was used as the out
group. The numbers in parentheses are the accession numbers of the gene sequences. Arrows indicate the position of strains from the abscess or
blood source in this case
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negative. AST for H. cinaedi isolates must be per-
formed for cases of CNS infections. When the MIC
value to ceftriaxone is 4 μg/mL or higher, treatment
failure can occur. Meropenem can be a first-line drug
of choice or an effective alternative treatment for H.
cinaedi CNS infections.
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